[Motivational interviewing : A possibility for doctor-patient communication in schizophrenia?]
„Motivational interviewing“ : Eine Möglichkeit der Arzt-Patienten-Kommunikation bei Schizophrenie?
Communication strategy
Doctor-patient communication
Medication adherence
Motivational Interviewing
Schizophrenia
Journal
Der Nervenarzt
ISSN: 1433-0407
Titre abrégé: Nervenarzt
Pays: Germany
ID NLM: 0400773
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
pubmed:
4
4
2019
medline:
21
11
2019
entrez:
4
4
2019
Statut:
ppublish
Résumé
Motivational interviewing (MI) has become established nowadays as an approach for a cooperative style of conversation to promote intrinsic motivation for change by exploring and resolving ambivalences. The change of addictive behavior is no longer sought by exerting pressure or lecturing/converting attempts of convincing or persuasion but by activating existing but "buried" or newly acquired self-motivation to change. The MI is now also used to change the treatment of other health-related behavior and chronic diseases, including schizophrenic disorders. Compared to the efficacy of MI in the addiction area, the data situation in schizophrenic patients is still insufficient. According to the available studies, MI can positively influence important aspects of disease-related impairments, such as medication adherence, the frequency and severity of psychotic relapses, the duration of hospitalization, the level of function, insight into the disease and cognitive rehabilitation. The practical implementation of MI requires a good knowledge of the method as well as changes in treatment principles and work processes.
Identifiants
pubmed: 30941459
doi: 10.1007/s00115-019-0702-x
pii: 10.1007/s00115-019-0702-x
doi:
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
1144-1153Références
Schizophr Res. 2014 Feb;152(2-3):408-14
pubmed: 23972821
Schizophr Bull. 2013 Nov;39(6):1242-51
pubmed: 24072808
BMC Psychiatry. 2018 May 18;18(1):135
pubmed: 29776393
BMJ. 2010 Nov 24;341:c6325
pubmed: 21106618
World J Biol Psychiatry. 2013 Feb;14(1):2-44
pubmed: 23216388
Schizophr Bull. 2010 Jan;36(1):94-103
pubmed: 19955388
Soc Sci Med. 1997 Mar;44(5):681-92
pubmed: 9032835
Br J Gen Pract. 2005 Apr;55(513):305-12
pubmed: 15826439
Trials. 2015 Jun 14;16:270
pubmed: 26072311
Psychiatr Prax. 2010 Sep;37(6):279-84
pubmed: 20552539
Schizophr Bull. 2016 Mar;42(2):327-34
pubmed: 26420905
Psychol Med. 2014 Oct;44(13):2749-61
pubmed: 25065535
Nervenarzt. 2017 Sep;88(9):995-1002
pubmed: 28597029
J Psychiatr Pract. 2010 Sep;16(5):306-24
pubmed: 20859108
Int J Epidemiol. 2017 Apr 1;46(2):589-602
pubmed: 27864410
Psychother Psychosom Med Psychol. 2018 Nov;68(11):481-494
pubmed: 30359995
World J Biol Psychiatry. 2015 Apr;16(3):142-70
pubmed: 25822804
J Nerv Ment Dis. 1999 Oct;187(10):630-5
pubmed: 10535657
Patient Educ Couns. 2017 Dec;100(12):2190-2199
pubmed: 28619271
Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56
pubmed: 15000267
J Clin Psychol. 2009 Nov;65(11):1232-45
pubmed: 19739205
Med Care. 2009 Aug;47(8):826-34
pubmed: 19584762
BMC Psychiatry. 2016 Apr 06;16:90
pubmed: 27048373
Front Psychol. 2016 Nov 14;7:1759
pubmed: 27895602
Psychiatr Prax. 2003 May;30(Suppl 2):136-139
pubmed: 13130358
J Consult Clin Psychol. 2003 Oct;71(5):843-61
pubmed: 14516234
J Subst Abuse Treat. 2014 Mar;46(3):340-5
pubmed: 24157087
Nervenarzt. 2015 May;86(5):637-46; quiz 647-8
pubmed: 25903501
Can J Psychiatry. 2017 Sep;62(9):624-634
pubmed: 28886671
Can J Psychiatry. 2011 Nov;56(11):643-50
pubmed: 22114918
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006936
pubmed: 20091612